Globus Med Inc Financials
This page shows Globus Med Inc (GMED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Globus Med Inc has an operating margin of 6.6%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 33/100, indicating healthy but not exceptional operating efficiency. This is down from 8.5% the prior year.
Globus Med Inc's revenue surged 60.6% year-over-year to $2.5B, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Globus Med Inc carries a low D/E ratio of 0.26, meaning only $0.26 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.54, Globus Med Inc holds $2.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
Globus Med Inc converts 16.1% of revenue into free cash flow ($405.2M). This strong cash generation earns a score of 80/100.
Globus Med Inc generates a 2.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 10/100. This is down from 3.1% the prior year.
Globus Med Inc scores 7.78, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.8B) relative to total liabilities ($1.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Globus Med Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Globus Med Inc generates $5.06 in operating cash flow ($520.6M OCF vs $103.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Globus Med Inc earns $39.6 in operating income for every $1 of interest expense ($166.0M vs $4.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Globus Med Inc generated $2.5B in revenue in fiscal year 2024. This represents an increase of 60.6% from the prior year.
Globus Med Inc's EBITDA was $420.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.2% from the prior year.
Globus Med Inc generated $405.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 145.2% from the prior year.
Globus Med Inc reported $103.0M in net income in fiscal year 2024. This represents a decrease of 16.2% from the prior year.
Globus Med Inc earned $0.75 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 29.9% from the prior year.
Globus Med Inc held $784.4M in cash against $0 in long-term debt as of fiscal year 2024.
Globus Med Inc's gross margin was 58.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 6.2 percentage points from the prior year.
Globus Med Inc's operating margin was 6.6% in fiscal year 2024, reflecting core business profitability. This is down 1.9 percentage points from the prior year.
Globus Med Inc's net profit margin was 4.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 3.7 percentage points from the prior year.
Globus Med Inc's ROE was 2.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the prior year.
Globus Med Inc invested $163.8M in research and development in fiscal year 2024. This represents an increase of 32.0% from the prior year.
Globus Med Inc spent $85.8M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 62.0% from the prior year.
Globus Med Inc invested $115.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 47.5% from the prior year.
GMED Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $769.0M+3.2% | $745.3M+24.6% | $598.1M-9.0% | $657.3M+4.4% | $629.7M+3.8% | $606.7M-1.6% | $616.5M+60.7% | $383.6M |
| Cost of Revenue | $252.5M+1.5% | $248.8M+27.3% | $195.4M-25.8% | $263.4M+1.3% | $260.0M+7.7% | $241.5M-9.0% | $265.5M+96.1% | $135.4M |
| Gross Profit | $516.5M+4.0% | $496.6M+23.3% | $402.7M+2.3% | $393.9M+6.5% | $369.7M+1.2% | $365.2M+4.0% | $351.0M+41.4% | $248.2M |
| R&D Expenses | $38.1M-4.7% | $40.0M+20.8% | $33.1M-1.0% | $33.4M-11.4% | $37.7M-34.2% | $57.3M+9.6% | $52.3M+78.2% | $29.3M |
| SG&A Expenses | $313.6M+3.3% | $303.6M+25.1% | $242.8M-4.0% | $252.9M+5.6% | $239.5M-3.7% | $248.7M+1.6% | $244.7M+56.7% | $156.2M |
| Operating Income | $137.4M+80.5% | $76.1M-21.5% | $97.0M+60.9% | $60.3M+21.5% | $49.6M+520.5% | $8.0M-21.0% | $10.1M+2405.7% | $404K |
| Interest Expense | $1.5M+110.0% | $693K-58.8% | $1.7M+106.3% | $815K+134.9% | -$2.3M-23.3% | -$1.9M+26.6% | -$2.6M-132.6% | $7.9M |
| Income Tax | $25.0M+270.6% | -$14.7M-152.0% | $28.2M+1634.6% | -$1.8M-111.6% | $15.8M+1197.9% | -$1.4M-114.5% | $10.0M+548.1% | $1.5M |
| Net Income | $119.0M-41.4% | $202.8M+168.8% | $75.5M+184.7% | $26.5M-16.5% | $31.8M+546.3% | -$7.1M-147.3% | $15.0M+1406.4% | $998K |
| EPS (Diluted) | $0.88-40.9% | $1.49+175.9% | $0.54+184.2% | $0.19-17.4% | $0.23+560.0% | $-0.05-600.0% | $0.010.0% | $0.01 |
GMED Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.1B+2.7% | $5.0B+5.3% | $4.7B-10.3% | $5.3B+5.2% | $5.0B+1.0% | $4.9B-2.8% | $5.1B-5.0% | $5.4B |
| Current Assets | $1.9B+11.2% | $1.7B+1.2% | $1.7B-21.5% | $2.2B+13.2% | $1.9B+5.2% | $1.8B-4.5% | $1.9B-0.1% | $1.9B |
| Cash & Equivalents | $371.8M+62.0% | $229.4M-50.3% | $461.3M-41.2% | $784.4M+91.1% | $410.4M+15.9% | $354.1M-24.2% | $467.3M+67.1% | $279.6M |
| Inventory | $771.5M-0.1% | $772.1M+16.4% | $663.6M+0.7% | $659.2M-14.4% | $770.5M-5.6% | $816.2M-3.8% | $848.1M-6.3% | $905.0M |
| Accounts Receivable | $619.1M+1.2% | $611.6M+14.3% | $535.1M-4.1% | $557.7M-8.8% | $611.8M+14.5% | $534.3M+6.2% | $503.2M+1.8% | $494.1M |
| Goodwill | $1.4B0.0% | $1.4B+0.1% | $1.4B0.0% | $1.4B-1.5% | $1.5B+0.2% | $1.5B+1.2% | $1.4B+27.8% | $1.1B |
| Total Liabilities | $696.8M+4.7% | $665.4M+6.8% | $623.1M-42.0% | $1.1B+5.6% | $1.0B-0.4% | $1.0B-6.1% | $1.1B-6.9% | $1.2B |
| Current Liabilities | $466.0M+9.7% | $424.7M+10.4% | $384.7M-55.1% | $855.9M+7.8% | $794.1M+1.0% | $786.3M+100.4% | $392.3M-8.5% | $428.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.4B+2.4% | $4.3B+5.1% | $4.1B-2.1% | $4.2B+5.1% | $4.0B+1.4% | $3.9B-1.9% | $4.0B-4.5% | $4.2B |
| Retained Earnings | $1.3B+6.5% | $1.2B+17.1% | $1.0B-10.1% | $1.2B+7.3% | $1.1B+2.6% | $1.0B-8.0% | $1.1B-15.6% | $1.3B |
GMED Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $249.7M+220.7% | $77.9M-56.1% | $177.3M-15.7% | $210.3M+287.7% | $54.3M+3.6% | $52.4M-50.0% | $104.7M+107.3% | $50.5M |
| Capital Expenditures | $35.8M-23.1% | $46.6M+29.0% | $36.1M+111.0% | $17.1M-38.4% | $27.8M-2.7% | $28.6M+24.9% | $22.9M+6.3% | $21.5M |
| Free Cash Flow | $213.9M+583.3% | $31.3M-77.8% | $141.2M-26.9% | $193.2M+630.3% | $26.5M+11.1% | $23.8M-70.9% | $81.8M+182.5% | $28.9M |
| Investing Cash Flow | -$75.8M+74.6% | -$299.1M-327.7% | $131.4M+226.2% | -$104.1M-903.3% | -$10.4M+77.7% | -$46.6M-114.5% | $320.6M+496.5% | -$80.9M |
| Financing Cash Flow | -$32.0M-28.5% | -$24.9M+96.1% | -$635.4M-1163.7% | $59.7M+585.9% | $8.7M+107.5% | -$115.7M+51.2% | -$237.3M-16750.5% | $1.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $40.0M+60.0% | $25.0M-86.9% | $190.5M+18945.1% | $1.0M-32.0% | $1.5M-98.2% | $83.3M | N/A | N/A |
GMED Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.2%+0.5pp | 66.6%-0.7pp | 67.3%+7.4pp | 59.9%+1.2pp | 58.7%-1.5pp | 60.2%+3.2pp | 56.9%-7.8pp | 64.7% |
| Operating Margin | 17.9%+7.7pp | 10.2%-6.0pp | 16.2%+7.1pp | 9.2%+1.3pp | 7.9%+6.6pp | 1.3%-0.3pp | 1.6%+1.5pp | 0.1% |
| Net Margin | 15.5%-11.8pp | 27.2%+14.6pp | 12.6%+8.6pp | 4.0%-1.0pp | 5.0%+6.2pp | -1.2%-3.6pp | 2.4%+2.2pp | 0.3% |
| Return on Equity | 2.7%-2.0pp | 4.7%+2.9pp | 1.8%+1.2pp | 0.6%-0.2pp | 0.8% | N/A | 0.4%+0.4pp | 0.0% |
| Return on Assets | 2.3%-1.8pp | 4.1%+2.5pp | 1.6%+1.1pp | 0.5%-0.1pp | 0.6%+0.8pp | -0.1%-0.4pp | 0.3%+0.3pp | 0.0% |
| Current Ratio | 4.13+0.1 | 4.07-0.4 | 4.45+1.9 | 2.54+0.1 | 2.42+0.1 | 2.33-2.6 | 4.88+0.4 | 4.47 |
| Debt-to-Equity | 0.160.0 | 0.150.0 | 0.15-0.1 | 0.260.0 | 0.260.0 | 0.26-0.0 | 0.270.0 | 0.28 |
| FCF Margin | 27.8%+23.6pp | 4.2%-19.4pp | 23.6%-5.8pp | 29.4%+25.2pp | 4.2%+0.3pp | 3.9%-9.3pp | 13.3%+5.7pp | 7.5% |
Similar Companies
Frequently Asked Questions
What is Globus Med Inc's annual revenue?
Globus Med Inc (GMED) reported $2.5B in total revenue for fiscal year 2024. This represents a 60.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Globus Med Inc's revenue growing?
Globus Med Inc (GMED) revenue grew by 60.6% year-over-year, from $1.6B to $2.5B in fiscal year 2024.
Is Globus Med Inc profitable?
Yes, Globus Med Inc (GMED) reported a net income of $103.0M in fiscal year 2024, with a net profit margin of 4.1%.
What is Globus Med Inc's earnings per share (EPS)?
Globus Med Inc (GMED) reported diluted earnings per share of $0.75 for fiscal year 2024. This represents a -29.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Globus Med Inc's EBITDA?
Globus Med Inc (GMED) had EBITDA of $420.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Globus Med Inc's gross margin?
Globus Med Inc (GMED) had a gross margin of 58.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Globus Med Inc's operating margin?
Globus Med Inc (GMED) had an operating margin of 6.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Globus Med Inc's net profit margin?
Globus Med Inc (GMED) had a net profit margin of 4.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Globus Med Inc's return on equity (ROE)?
Globus Med Inc (GMED) has a return on equity of 2.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Globus Med Inc's free cash flow?
Globus Med Inc (GMED) generated $405.2M in free cash flow during fiscal year 2024. This represents a 145.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Globus Med Inc's operating cash flow?
Globus Med Inc (GMED) generated $520.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Globus Med Inc's total assets?
Globus Med Inc (GMED) had $5.3B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Globus Med Inc's capital expenditures?
Globus Med Inc (GMED) invested $115.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Globus Med Inc spend on research and development?
Globus Med Inc (GMED) invested $163.8M in research and development during fiscal year 2024.
Does Globus Med Inc buy back shares?
Yes, Globus Med Inc (GMED) spent $85.8M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
What is Globus Med Inc's current ratio?
Globus Med Inc (GMED) had a current ratio of 2.54 as of fiscal year 2024, which is generally considered healthy.
What is Globus Med Inc's debt-to-equity ratio?
Globus Med Inc (GMED) had a debt-to-equity ratio of 0.26 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Globus Med Inc's return on assets (ROA)?
Globus Med Inc (GMED) had a return on assets of 2.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Globus Med Inc's Altman Z-Score?
Globus Med Inc (GMED) has an Altman Z-Score of 7.78, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Globus Med Inc's Piotroski F-Score?
Globus Med Inc (GMED) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Globus Med Inc's earnings high quality?
Globus Med Inc (GMED) has an earnings quality ratio of 5.06x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Globus Med Inc cover its interest payments?
Globus Med Inc (GMED) has an interest coverage ratio of 39.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Globus Med Inc?
Globus Med Inc (GMED) scores 67 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.